The FDA granted accelerated approval to the nuclear transport inhibitor selinexor in combination with the corticosteroid dexamethasone for patients with relapsed or refractory multiple myeloma. Marketed as Xpovio, the drug is indicated for patients treated with at least 4 prior therapies whose disease has developed resistance to other treatments, including at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Voelker R. Combination Approved for Advanced Multiple Myeloma. JAMA. 2019;322(5):393. doi:10.1001/jama.2019.11155
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: